Medtronic (NYSE:MDT) recently reported its Q3 fiscal 2019 results, which were above our estimates. The company saw steady growth in most of its business segments. However, Cardiac & Vascular Group, which includes rhythm management devices, and balloons, among other products, saw a modest decline...
Medtronic (NYSE:MDT) recently reported its Q3 fiscal 2019 results, which were above our estimates. The company saw steady growth in most of its business segments. However, Cardiac & Vascular Group, which includes rhythm management devices, and balloons, among other products, saw a modest decline...
Share this Article
Recommended